RxDoctor Payments Data

Mary Ann Sayon

Gerontology · Hemet, CANPI 1164028080

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,399 of the $8,545 with a category attached, or 86.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,545in general payments, 2019–2025

Across 346 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$925
  • Corcept Therapeutics$854
  • Amgen$794
  • AstraZeneca$672
  • Johnson & Johnson$529
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$8009%
  • Travel & lodging$3214%
  • Food & beverage$7,39987%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,545 in reported general payments places this provider in the 95th percentile of 348 gerontology providers in California.

See all gerontology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone34$657,250
JardianceEmpagliflozin60$88,566
IsturisaOsilodrostat Phosphate14$67,795
EntrestoSacubitril/Valsartan51$57,219
XareltoRivaroxaban40$39,002
OzempicSemaglutide43$38,895
FarxigaDapagliflozin Propanediol39$35,929
VraylarCariprazine Hcl18$34,542
KerendiaFinerenone38$32,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$27,194
TrulicityDulaglutide23$26,220
Nurtec OdtRimegepant Sulfate18$19,095
Repatha SureclickEvolocumab14$18,786
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,023
RexultiBrexpiprazole11$15,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$854$657,25034 claims
Boehringer IngelheimJardiance$282$88,56660 claims
Recordati_rare_diseases_inc.Isturisa$489$67,79514 claims
NovartisEntresto$106$57,21951 claims
AstraZenecaFarxiga, Breztri Aerosphere$672$51,95266 claims
Lilly USA, LLCTrulicity, Mounjaro$54$41,49436 claims
Johnson & JohnsonXarelto$529$39,00240 claims
Novo NordiskOzempic$245$38,89543 claims
AbbVieVraylar$925$34,54218 claims
BayerKerendia$307$32,10438 claims
GSKTrelegy Ellipta$62$27,19444 claims
PfizerNurtec Odt$62$19,09518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 gerontology providers in California.

Other gerontology in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →